U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Kemper AR, Coeytaux R, Sanders GD, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Sep. (Comparative Effectiveness Reviews, No. 28.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA)

Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) [Internet].

Show details

Appendix CData Abstraction Forms

KQ 1–4—Blank ET/Data Abstraction Form

StudyInterventions and study designPatient characteristicsResultsComments/quality/applicability
StudyIDGeographical location:

Study dates:

Funding source:

Setting:

Study design:
RCT
Nonrandomized comparative study
Other

Intervention(s):
-

DMARD name:

-

Dose:

-

Titration:

-

N:

Comparator(s):

Were additional arthritis medications allowed?:

If Yes to above, was this done:
Per protocol At discretion of clinician/investigator NR

Study duration:

Primary outcome(s):

Secondary outcome(s):		Number of patients:
-

Screened for inclusion:

-

Eligible for inclusion:

-

Randomized:

-

Began treatment:

-

Completed treatment:

-

Withdrawals/losses to followup:

Age:
-

Mean (SD):

-

Median:

-

Range:

Sex:
-

Female:

-

Male:

Race/ethnicity:

JIA diagnosis:
JRA
JCA
JIA
Spondyloarthropathy
Psoriatic arthritis
Other (describe)

Baseline severity:
Active joint count:
Duration of disease:
Other (specify):
NR

Percentage with uveitis:

Inclusion criteria:

Exclusion criteria:
  1. Active joint count:
  2. Quality of life/functional status:
  3. Number of joints with limited range of motion:
  4. Global assessment of current status:
    -

    Physician:

    -

    Patient/Parent:

  5. Laboratory measures of inflammation:
    -

    ESR:

    -

    Other:

  6. Radiographic evidence of progression of disease:
  7. Pain control:
  8. Clinical remission:
  9. Flare of disease:
  10. Discontinuation of DMARD due to:
    -

    Remission of disease:

    -

    Inefficacy:

    -

    Intolerance/AEs:

  11. Mortality:
  12. Adverse events reported?:
    • Yes
    • No
  13. Other:
Exclusion reasons (if appropriate):

General comments:

Quality assessment:
Primary outcome:
-

Overall rating:

-

Comments:

Adverse events:
-

Overall rating:

-

Comments:

Applicability:

This article is relevant to:
Question #_____

KQ 5—Blank ET/Data Abstraction Form

StudyStudy designPatient characteristicsInstrument(s)ResultsComments/quality/applicability
StudyIDGeographical location:

Setting:
Specialty clinic Other [specify]

Study design:
RCT
Longitudinal non-RCT
Cross-sectional
Other [specify]

Study objective(s):

Duration of followup:		Number of patients:

Age:
-

Mean (SD):

-

Median:

-

Range:

Sex:
-

Female:

-

Male:

Race/ethnicity:
JIA diagnosis:
JRA
JCA
JIA
Spondyloarthropathy
Psoriatic arthritis
Other (describe)

Percentage with systemic JIA:

Baseline severity:
Time since diagnosis:
Active joint count:
Other [specify]:
NR

Inclusion criteria:

Exclusion criteria:		Instrument(s) evaluated:

Mode of administration:
Self-administered
Interviewer-administered
Other [specify]		1) Reliability:
-

Test-retest:

-

Kappa statistics:

-

Inter-rater:

-

Intra-rater:

-

Intra-class correlation:

2) Validity:
-

Versus clinical outcomes:

-

Versus lab results:

-

Versus radiological results:

-

New instrument versus established instrument:

3) Other:
-

Feasibility: NR [or report results]

-

Responsiveness: NR [or report results]

-

ROC curves: NR [or report results]

Exclusion reasons (if appropriate):

General comments:

Quality assessment:

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (4.5M)

Other titles in these collections

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...